Leishmaniavirus genetic diversity is not related to leishmaniasis treatment failure.
Genotype
LRV1
Leishmania guyanensis
Pentamidine
Treatment failure
Journal
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
12
12
2019
revised:
24
04
2020
accepted:
26
04
2020
pubmed:
8
5
2020
medline:
13
7
2021
entrez:
8
5
2020
Statut:
ppublish
Résumé
The outcome of American tegumentary leishmaniasis (ATL) may depend on the presence of the Leishmania RNA virus (LRV). This virus may be involved in treatment failure. We aimed to determine whether genetic clusters of LRV1 are involved in this therapeutic outcome. The presence of LRV1 was assessed in 129 Leishmania guyanensis isolates from patients treated with pentamidine in French Guiana. Among the 115 (89%) isolates found to carry LRV1, 96 were successfully genotyped. Patient clinical data were linked to the LRV data. The rate of treatment failure for LRV1-positive isolates was 37% (15/41) versus 40% (2/5) among LRV1-negative isolates (p 0.88). Concerning LRV1 genotypes, two predominant LRV1 groups emerged, groups A (23% (22/96)) and B (70% (67/96)). The treatment failure rate was 37% (3/8) for group A and 45% (9/20) for group B (p 0.31). Neither the presence nor genotype of LRV1 in patients with L. guyanensis seemed to correlate with pentamidine treatment failure.
Identifiants
pubmed: 32380286
pii: S1198-743X(20)30265-2
doi: 10.1016/j.cmi.2020.04.037
pii:
doi:
Substances chimiques
Pentamidine
673LC5J4LQ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
286.e1-286.e5Informations de copyright
Copyright © 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.